PDCD1 and neoplasm: Prolonged immunotherapy can elevate PD-1 expression in CD4+ and CD8+ T cells, leading to reduced infiltration of these cells into the tumor and decreased levels of activation markers such as IFNγ, TNFα, and granzyme B [61].